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Does being on TB treatment predict a higher burden of problems and concerns 
among HIV outpatients in Kenya? A cross-sectional self-report study 
 
Tuberculosis illness is associated with uncertain outcomes, and has high prevalence 
among people living with HIV. The new World Health Organization’s End TB strategy 
specifies person-centred symptom management and psychosocial support alongside 
treatment within its pillars and components. There is a paucity of research to inform an 
effective care response in Kenya in terms of self-reported outcomes. We aimed to 
measure the three day period intensity of problems and concerns (physical, 
psychological, social and spiritual), and identify predictors of problems and concerns, 
among HIV patients attending outpatient care.  
We conducted a cross-sectional self-report quantitative study among adult (aged at least 
18 years) patients with confirmed HIV diagnosis, and aware of their diagnosis and 
attending HIV outpatient care in Kenya. Multi-dimensional palliative care problems and 
concerns were collected using African Palliative Outcome Scale (APOS). Ordinal logistic 
regression assessed the association of multi-dimensional problems and concerns 
controlling for demographic variables (age, gender, education and wealth) and clinical 
variables (WHO clinical stage, HIV treatment status, TB treatment status, and CD4 
count).  
We recruited N=400 participants. N=61 (15.64%) were on TB treatment. The items with 
worst score responses were help and advice to plan for the future (52.5%), ability to 
share feelings (46.25%), at peace (30.75%) pain (27%) and life worthwhile (18.75%). 
TB treatment status was associated with lower (worse) score for APOS total score (odds 
ratio .59, 95% CI .36 to .99; P=0.046) and factor 3(existential and spiritual wellbeing: 
.55, .32 to .92; p=0.023). Interestingly higher CD4 count was predictive of lower 
(worse) factor 3 outcomes (existential and spiritual wellbeing: .84, 95% CI 73 to .97; 
p=0.014).  
2 
 
This study informs the new WHO End TB policy with novel data on specific clinical needs. 
This calls for holistic symptom assessment, person-centred care and holistic 
management to respond positively to the End TB strategy.  
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Introduction 
Kenya has the fourth largest HIV epidemic with 1.6 million people living with HIV (PLWH) 
(UNAIDS, 2016). Kenya also has highest prevalence of TB. Current data shows that there 
are 558 TB cases per 100,000 people (Voice of Africa, 2017). 
Having HIV increases the likelihood of developing active pulmonary TB by 20 to 30 times 
(WHO, 2017). One third of HIV positive people in 2015 were infected with TB in Kenya. 
WHO  global report suggested that Kenya is the one of the high burden TB countries (WHO, 
2016). It is on top 20 on the lists of: (1) highest estimated number of incident TB 
cases >10,000 per year, (2) highest estimated numbers of incident TB cases among 
PLWH >1000 per year, and (3) highest estimated numbers of incident MDR-TB 
cases >1000 per year (WHO, 2015b). Approximately 30% of TB cases in Kenya are HIV 
positive (UNAIDS, 2016). TB is the fourth leading cause of death in Kenya (WHO, 2017). 
WHO estimated that in 2015, 35% of the deaths in HIV were related to TB (WHO, 2017). 
UNAIDS sustainable development goal calls for the end of the global TB epidemic by 2030 
including 90% reduction in TB deaths and 80% reduction in TB incidence rate.  In order 
to achieve these goals the strategy proposes integration of TB and palliative care services. 
The new WHO End TB strategy calls for palliative care to attain zero suffering and 
advocates for access palliative care at each stage of the illness (WHO, 2015a). We aimed 
to measure problems and concerns among HIV patients attending outpatient clinic. The 
objectives were: (1) measure the three day period intensity of problems and concerns 
(physical, psychological, social and spiritual), and (2) identify predictors of problems.   
Methods 
Study design and participants 
We did a cross-sectional study using self-report and file extraction among HIV/AIDS 
participants attending outpatient clinic at BOMU community hospital in Mombasa, Kenya. 
Adults (aged at least 18 years) with confirmed HIV diagnosis, and aware of their 
4 
 
diagnosis were included. We excluded those with significant physical or psychological 
impairment such that they were unable to give self-report data.  Ethical approval was 
obtained from Kenyan Medical Research Institute (KEMRI/RES/7/3/1). 
Data collection 
We extracted CD4, treatment status for HIV and TB from patient’s records.  The other 
data was self-report and was collected in a private space at the clinic. All responses were 
recorded and answers given verbally by participants. This helped to reduce any potential 
response bias by mixing self-completion and research-completion. Data were collected 
using tools previously implemented/validated in African in HIV populations. The tools 
were: 
1. Demographics, socioeconomic status using Demographic and Health Survey (DHS) 
(Gwatkin et al., 2007) and has previously been used in HIV research in sub-Saharan 
Africa (Lowther et al., 2012).  
2. The African Palliative care Outcome Scale (APOS) was used to measure 3 day period 
of symptoms and concerns. It consists of seven items, scored on a 6-point (0-5) Likert 
scale. Possible scores range from 0-35 (with some items reversed), higher scores 
indicating the most positive outcomes (Harding et al., 2010). APOS had three validated 
subscales: (1) Physical and psychological wellbeing subscale (2) Interpersonal well-being 
subscale and (3) Existential well-being subscale (Harding et al., 2013).  
Sample size calculation 
Sample size calculation was based on HIV prevalence in Kenya. UNAIDS data report that 
1.5 million Kenyans are infected with HIV (95% CI 1.3m, 1.6m) (WHO/UNAIDS, 2015). 
With 95% confidence, 5% margin of error, and a response distribution of 50% for any 
outcome we estimated that 385 were required to determine prevalence of any outcome 
(physical/ psychological symptom). We therefore recruited 400 to allow for any non-
completers.  
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Data analysis 
Data was entered into a spreadsheet with a unique identifier for each patient. The 
spreadsheet was converted into Stata version 14 dataset (StataCorp, 2015).  
Descriptive statistics were used to profile the demographic, socioeconomic and clinical 
characteristics of participants. APOS scores were tabulated. All APOS subscales were 
computed and calculated based on the methods of APOS factor rather than just using 
APOS total scores which could potentially mask differences between domains.  Because 
APOS total scores and factors 1, 2 and 3 were not normally distributed, they were 
converted into textiles.  WHO clinical stages were combined (I and II combined to one 
group, likewise III and IV, because of small numbers).  
Initial steps involved conducting a series of univariate analysis (ordered logistic regression) 
for demographic and clinical variables. The second step involved conducting multivariate 
analysis  adjusting for demographic variables falling within less than 25% p value (Altman, 
1991). All clinical variables were forced into the model regardless on the outcome of the 
univariate analysis because they important disease biomarkers which define HIV/AIDS 
state. We conducted a ‘brant’ test of parallel regression assumption. A non-significant test 
statistic provided evidence that the parallel regression assumption were met. All cases 
with missing data were excluded from the analysis. 
Results  
Sample characteristics and treatment variables  
Table 1 presents the demographic characteristics and treatment variables of the 
participants. Of the 475 participants approached, 400 (84.2%) participated. The sample 
mean age was 39.4 years (SD 9.9).  
Most of the patients were currently on ART (n=366, 91.5%), with (n=61, 15.64%) 
concurrent TB treatment. The mean CD4 count was 393.7(SD=238.2) range 2-1470. 
Most of the participants were at stage III/IV of HIV infection (n=348, 87%).   
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Table 1: Demographic and clinical characteristics (N=400) 
Demographic characteristics 
Mean age (SD) 39.4 (9.9) 
Female gender 280 (70%) 
  Education   
    Primary  
    Secondary 
    Tertiary  
   
258 (64.5%) 
113 (28.25%) 
  29 (7.25%) 
Wealth quintile 
   Poorest 
   Middle poor 
   Middle 
   Middle wealthy 
   Wealthiest  
 
101 (25.25%) 
  59 (14.75%) 
  80 (20%) 
  80 (20%) 
  80 (20%) 
Clinical characteristics  
Physical performance (KPF) 
 Mean(SD) 
 Range 
 
89.95 (13.53) 
40-100 
CD4 count 
    Mean(SD)  
    Range 
 
393.7 (238.2) 
2-1470 
WHO Stage 
   Stage 1 and 2 
   Stage 3 and 4 
 
  52 (13%) 
348 (87%)   
Patient on ART 
  Yes  
  No 
 
366 (91.5%) 
  34 (8.5%) 
Patient on TB treatment1 
   Yes 
    No 
 
 61 (15.64%) 
329 (84.36%) 
Behavioural characteristics 
Told someone HIV Status 373 (93.25%) 
Missed ART doses in the past 7 days2 
   Yes 
   No 
   Mean(SD) 
   Range (number of missed doses)  
 
64 (16%) 
302 (75.5%) 
0.36 (1.28) 
1-14 
APOS total scores, mean(SD) (0-35)3 21.45 (7.46) 
APOS factor 1: Physical and psychological well-being, mean(SD) (0-15)
3
 10.66 (4.42) 
APOS factor 2: Interpersonal well-being, mean(SD) (0-10)
3
   4.11 (3.18) 
APOS factor 3: Existential and spiritual well-being, mean(SD) (0-10)
3
   6.68 (3.51) 
 
Table 2: APOS (problems and concerns) reporting previous 3 days (n=400) 
 
                                                          
1 10 missing 
2 34 not on ART 
3 APOS: African Palliative  Outcomes Scale, high scores better status 
POS Item 0(worst 
status) 
1 2 3 4 5 (Best 
status) 
Mean(SD) 
Pain 51 (12.75%)   57 (14.25%) 39(9.75%) 51(12.75%) 37(9.25%) 165(41.25%) 3.15(1.88) 
Symptoms 27 (6.75%) 35 (8.75%) 37(9.25%) 54(13.5%) 47(11.75%) 200(50%) 3.65(1.66) 
Worry 45 (11.25%) 16 (4%) 23(5.75%) 38(9.5%) 24(6%) 254(63.5%) 3.86(1.76) 
Share feelings 159 (39.75%) 26 (6.5%) 32(8%) 37(9.25%) 22(5.5%) 124(31%) 2.27(2.17) 
Life worthwhile 63 (15.75%) 12 (3%) 19(4.75%) 32(8%) 44(11%) 230(57.5%) 3.68(1.88) 
Peace 93 (23.25%) 30 (7.5%) 24 (6%) 50(12.5%) 43(10.75%) 160(40%) 3(2.04) 
Help and advise  193 (48.25%) 17(4.25%) 27(6.75%) 46(11.5%) 59(14.75%) 58(14.5%) 1.84(1.99) 
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Predictors of problems and concerns 
Following univariate analysis (table 3), multivariate models were constructed (table 4).  
TB treatment was associated with worse symptoms and concerns (APOS total score: odds 
ratio (OR) .59, 95% CI .36 to .99; P=0.046) and factor 3 (existential and spiritual 
wellbeing: .55, 95% CI .32 to .92; p=0.023).  Interestingly a higher CD4 count was 
predictive of lower (worse) scores for factor 3 (existential and spiritual wellbeing: OR .84, 
95% CI 73 to .97; p=0.014).   
Age was predictive of higher (better) scores for palliative care symptoms and concerns 
(APOS total scores: OR 1.03; p= 0.005), factor 2 (interpersonal wellbeing: OR 1.03; 
p=0.004), and factor 3 (existential and spiritual wellbeing: OR 1.03; p=0.001).   
Female gender was predictive of lower (worse) scores for factor 1 (physical and 
psychological wellbeing: OR .59; p=0.013).  
Table 3: Univariate association of socio-demographic and clinical variables with 
POS total score and POS factors as dependent variables (n=390) 
Independent variables  Outcomes (dependent variables  
 APOS total Factor 1: (physical and 
psychological) 
Factor 2: 
interpersonal well-
being 
Factor 3: existential 
and spiritual  
 OR (95% CI) 
p value 
OR (95% CI) 
p value 
OR (95% CI) 
p value 
OR (95% CI) 
p value 
Age 1.03 (1.02 to 1.05) 
0.002* 
1.01 (.99 to 1.03) 
0.28 
1.03 (1.01 to 1.05) 
0.003* 
1.03 (1.01 to 1.05) 
0.001* 
Gender (ref female) .68 (.46 to 1.01) 
0.059* 
.57 (.38 to .85) 
0.006* 
1.28 (.86 to 1.91) 
0.23* 
.75 (.50 to 1.13) 
0.17* 
Clinical stage (stage 1/2 
vs stage 3/4) 
.79 (.46 to 1.36) 
0.40 
1.30 (.76 to 2.22) 
0.96 
.75 (.44 to 1.25) 
0.27 
1.16 (.68 to 1.98) 
0.59 
ART (ref yes) 1.49 (.77 to 2.87) 
0.23* 
1.76 (.92 to 3.37) 
0.086* 
1.37 (.71 to 2.63) 
0.35 
1.37 (.72 to 2.62) 
0.34 
CD4 count .93 (.83 to 1.05) 
0.25* 
.98 (.87 to 1.11) 
0.78 
.96 (.84 to 1.09) 
0.51 
.88 (.78 to 1.01) 
0.072* 
TB treatment (ref yes) .57 (.35 to .95) 
0.029* 
.62 (.37 to 1.02) 
0.059* 
.92 (.56 to 1.54) 
0.77 
.56 (.34 to .94) 
0.027* 
Education: Primary vs 
Secondary  
1.13 (.76 to 1.70) 
0.54 
1.18 (.78 to 1.78) 
0.43 
1.36 (.91 to 2.04) 
0.14* 
.72 (.47 to 1.08) 
0.12* 
Primary vs Tertiary 1.64 (.81 to 3.31) 
0.17* 
1.24 (.64 to 2.41) 
0.53 
1.49 (.75 to 2.97) 
0.26 
1.04 (.50 to 2.16) 
0.91 
Wealth: Poorest vs middle 
poor 
1.77 (.98 to 3.19) 
0.056 
1.95 (1.09 to 3.51) 
0.025* 
1.59 (.87 to 2.88) 
0.13 
1.29 (.70 to 2.35) 
0.41 
Poorest vs middle 1.42 (.82 to 2.25) 
0.21* 
1.73 (1.01 to 2.97) 
0.046* 
1.06 (.61 to 1.82) 
0.84 
1.19 (.69 to 2.06) 
0.53 
Poorest vs middle wealthy 1.60 (.92 to 2.76) 
0.095* 
1.37 (.80 to 2.36) 
0.25* 
1.85 (1.09 to 3.15) 
0.023* 
1.14 (.66 to 1.94) 
0.64 
Poorest vs wealthiest .93 (.54 to 1.59) 
0.78 
1.29 (.74 to 2.22) 
0.37 
1.57 (.91 to 2.70) 
0.11* 
.67 (.39 to 1.17) 
0.16* 
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POS: African Palliative Outcome Scale; CI: confidence interval  
*Significant at the 25% level and subsequently entered into the multivariable model  
 
Table 4: Multivariate analyses for total POS scores and POS factors as 
dependent variables (n=390) 
APOS: African Palliative Care Scale; CI: Confidence interval; TB: Tuberculosis 
Significant at *5% level, **1% level 
 
 
 
 
 
 
 
 
 
Independent variables  Outcomes (dependent variables  
 APOS total Factor 1: (physical and 
psychological) 
Factor 2: 
interpersonal well-
being 
Factor 3: existential 
and spiritual  
 OR (95% CI) 
p value 
OR (95% CI) 
p value 
OR (95% CI) 
p value 
OR (95% CI) 
p value 
Age 1.03 (1.01 to 1.05) 
0.005* 
- 1.03 (1.01 to 1.05) 
0.004* 
1.03 (1.01 to 1.06) 
0.001** 
Gender (ref female) .69 (.47 to 1.05) 
0.081 
.59 (.39 to .89) 
0.013* 
1.41  (.93 to 2.14) 
0.11 
.72 (.47 to 1.11) 
0.14 
Clinical stage (stage 1/2 
vs stage 3/4) 
.79 (45 to 1.38) 
0.41 
1.17 (.67 to 2.05) 
0.57 
.84 (.49 to 1.43) 
0.51 
1.22 (.69 to 2.13) 
0.50 
ART (ref yes) 1.30 (.66 to 2.56) 
0.44 
1.63 (.84 to 3.17) 
0.15 
1.10 (.56 to 2.16) 
0.78 
1.16 (.59 to 2.27) 
0.67 
CD4 count .91 (.80 to 1.04) 
0.16 
.98 (.86 to 1.11) 
0.72 
.94 (.82 to 1.07) 
0.36 
.84 (.73 to .97) 
0.014* 
TB treatment (ref yes) .59 (.36 to .99)  
0.046* 
.61 (.37 to 1.02) 
0.059 
.97 (.57 to 1.63) 
0.90 
.55 (.32 to .92) 
0.023* 
Education: Primary vs 
Secondary  
1.01 (.65 to 1.54) 
0.98 
- 1.26 (.82 to 1.93) 
0.29 
.67 (.43 to 1.04) 
0.071 
Primary vs Tertiary 1.78 (.84 to 3.76) 
0.13 
- 1.37 (.66 to 2.85) 
0.40 
1.22 (.56 to 2.68) 
0.62 
Wealth: Poorest vs middle 
poor 
1.70 (.93 to 3.10) 
0.083 
1.77 (.97 to 3.22) 
0.061 
1.59 (.86 to 2.92) 
0.14 
1.26 (.67 to 2.35) 
0.47 
Poorest vs middle 1.24 (.71 to 2.17) 
0.45 
1.69 (.97 to 2.92) 
0.062 
.97 (.56 to 1.70) 
0.93 
1.05 (.60 to 1.86) 
0.86 
Poorest vs middle wealthy 1.36 (.77 to 2.42) 
0.29 
1.32 (.75 to 2.30) 
0.33 
1.74 (1.00 to 3.04) 
0.051 
1.02 (.58 to 1.82) 
0.94 
Poorest vs wealthiest .74 (.41 to 1.34) 
0.32 
1.15 (.66 to 2.02) 
0.63 
1.35 (.75 to 2.41) 
0.32 
.60 (.33 to 1.11) 
0.11 
Tests of parallel regression 
assumption 
Brant test =5.99 
p=0.92 
Brant test =9.81 
p=0.37 
Brant test =16.62 
p=0.17 
Brant test =15.5 
p=0.22 
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Discussion 
Our study presents novel data on problems and concerns among HIV patients attending 
outpatient clinic in Kenya. Sample size was larger in our study compared to other studies 
conducted in sub-Saharan region (Harding, Defilippi, & Cameron, 2016). Recruitment rate 
was highly successful (84.2%). However this was a cross-sectional study, therefore we 
can only identify associations, not causality. We excluded participants who were unable to 
complete questionnaires with assistance from our data collector, therefore this data may 
underestimate the prevalence and burden of the multidimensional problems and concerns.  
The significant existential and spiritual wellbeing experienced by patients on TB treatment 
confirms the need for personal-centred care for patients (Harding et al., 2016). WHO 
recommends palliative care approach among patients on TB treatment (WHO, 2017). 
Existing professionals providing palliative care for HIV, cancer can translate directly into 
TB. The significant worsening in existential and spiritual wellbeing scores by patients with 
high CD4 counts confirms that clinically the patient may be better but may have spiritual 
problems. ART can only improve the immune system/increase the CD4 count, but the 
spiritual needs still persist. This calls for holistic management for patients even though 
they may have a strong immune system. A cross-sectional study among HIV (81%) and 
cancer (18%) conducted in Uganda and South Africa reported 27% burden of worst peace 
scores (Selman, Harding, Higginson, Gysels, & Speck, 2011).  
Palliative care services are needed among patients with HIV and TB to improve quality of 
life through integration of HIV and TB care and providing holistic and individualised care, 
through reducing stigma associated with TB treatment, and compassionate care (Hospice 
Palliative Care Association of South Africa, 2011). The provision of TB care focussing solely 
on technical aspects of care is not enough to meet the needs of patients on TB treatment 
(Harding et al., 2005). Palliative care helps to control symptoms associated with TB and 
comorbidities such as neuropathy due to side effects of Isoniazid (Breen, Lipman, & 
Johnson, 2000). Palliative care approach will help to improve patient’s well-being and 
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promote drug adherence. Poor drug adherence in TB leads to development of MDR-TB 
which is more costly and requires highly toxic drugs (Harding et al., 2016).  
A systematic review reported that HIV palliative care for chronic illnesses including TB 
improves problems and concerns (Harding et al., 2005). Previous evidence among cancer 
and HIV patients including their families show that palliative care services improves 
outcomes (Higginson & Evans, 2010). We therefore recommend integration of palliative 
care for TB alongside existing services such as HIV. Our novel data informs clinical practice 
to implement guidelines for providing palliative care to patients with TB and the new WHO 
End TB strategy (Hospice Palliative Care Association of South Africa, 2011; WHO, 2015a). 
All health workers must receive training in palliative care to equip them with skills to 
undertake routine assessments of patients with TB such as pain and symptom and provide 
appropriate interventions and support for their problems.  
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